Drug Profile
Rhenium Re 188 etidronate - Jiangsu Lai Tai Medical Biotechnology
Alternative Names: 188Re -HEDP; Etidronate-Re-188; Etidronate-Rhenium-188; Re-188-etidronate; Re-188-etidronic-acid; Re-188-HEDP; Rhenium-188-HEDPLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Jiangsu Lai Tai Medical Biotechnology
- Developer Jiangsu Lai Tai Medical Biotechnology; Shanghai Institute of Applied Physics Chinese Academy of Sciences
- Class Antineoplastics; Bisphosphonates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer pain
Most Recent Events
- 14 Oct 2021 Phase II development is ongoing in China (Shanghai Yi Tai Pharmaceutical Technology Company Ltd website, October 2021)
- 07 Jan 2016 Phase-II clinical trials in Cancer pain in China (IV)